Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Quipt Home Medical Corp T.QIPT

Alternate Symbol(s):  QIPT

Quipt Home Medical Corp. is a home medical equipment provider. The Company specializes in improving the home management of chronic illness through the application of telehealth systems and automated distribution. It provides in-home monitoring and disease management services, including end-to-end respiratory solutions for patients in the United States. It offers nebulizers, oxygen concentrators... see more

TSX:QIPT - Post Discussion

Quipt Home Medical Corp > Success on H.R. 6641 could have wide-ranging impacts
View:
Post by LionGate7 on May 05, 2022 6:56pm

Success on H.R. 6641 could have wide-ranging impacts

H.R. 6641’S REIMBURSEMENT RIPPLE EFFECT

Success on H.R. 6641 could have wide-ranging impacts on DME reimbursement across a spectrum of payers far beyond Medicare. It’s essential that providers help raise the visibility of the bill.

Fighting for sustainable reimbursement rates from Medicare and other major payers is a top priority for the American Association for Homecare. Without reimbursement rates that take into account higher prices for products and other increased operational costs, the HME community cannot fully realize our potential to meet the needs of the growing population of individuals who need home-based care.

Currently, we are working on two legislative initiatives to boost rates. H.R. 6641, introduced in February of this year, would apply a 90/10 blended rate for Medicare reimbursements in CBAs, which we estimate would boost reimbursements for items covered under the bidding program by 9.3 percent, on average.

For suppliers in non-rural, non-bid areas, we are working with Senate HME champions to build support for extending a 75/25 blended rate currently in effect in those areas beyond the end of the COVID-19 PHE. 


Taken with our success in continuing the 50/50 blended rate for suppliers in rural areas indefinitely, success on these two fronts would mean better, more-sustainable rates for Medicare suppliers everywhere. What’s more, securing H.R. 6641’s 90/10 blended rate for former CBAs would ripple through a broad spectrum of payers who peg their rates to the Medicare fee schedule.

Passing H.R. 6641 would also boost Medicaid and TRICARE rates that are directly tied to the Medicare fee schedule and could also impact other third-party insurers/private payers, including Medicare Advantage plans, that use Medicare rates as a factor in their rate-making. 

Helping Build the Case 

We need every HME stakeholder on board to raise the visibility of reimbursement legislation on Capitol Hill. We need every voice if we are going to stand out among the multitudes of competing legislative initiatives and political issues facing the House and Senate.

Please reach out to your House members in support of H.R. 6641. You can find details on how to make a case for this legislation at our Medicare Reimbursement Legislation Campaign Central.

In addition, if your Senator is one of 28 members of the Senate Finance Committee, your advocacy for extending the 75/25 blended rates in non-rural, non-bid areas will be critical. Look for more information on how you can support those efforts soon.

With the last two rounds of the bidding program effectively abandoned, we have a unique opportunity to make a case for Medicare reimbursement rates that reflect market reality – and to ultimately impact a wide spectrum of rates from other public and private payers. We can’t afford to miss this chance to put HME rate-making on a more sustainable footing for 2023 and beyond.


About the Author

Tom Ryan is the president and CEO of the American Association for Homecare (Washington, D.C.), the industry's national association.

Comment by gibbonsj on May 05, 2022 9:57pm
Good read. Thanx
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities